Associated tags: Software, Spectrum, Patient, OGM, Biology, Genome, Medicine, SAN, Genomics, Doctor of Philosophy, Research
Locations: SWITZERLAND, MASSACHUSETTS, HAMILTON, NEVADA, LONG, UNITED STATES, UKRAINE, RUSSIA, GEORGIA, SPAIN, LOS ANGELES, RENO, NEW YORK CITY, ISRAEL, SAN DIEGO, CA, US, BEIJING, NEW YORK, CHINA, FLORIDA
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
Key Points:
- To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
- An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
- Bionano is a life sciences instrumentation company in the genome analysis space.
- The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools.
Retrieved on:
Thursday, October 24, 2019
Neurological disorders,
Rare diseases,
Branches of biology,
Organ systems,
Facioscapulohumeral muscular dystrophy,
Muscular dystrophy,
RTT,
C9orf72,
Cytogenetics,
GeneDx,
Amyotrophic lateral sclerosis,
Hematology Joe Devaney, Ph.D., Associate Director of R&D of diagnostic company GeneDx presented a Saphyr validation study for the detection of the disease-causing variants in FSHD and repeat expansion disorders such as Mytonic Dystrophy 1 and 2.
Key Points:
- Joe Devaney, Ph.D., Associate Director of R&D of diagnostic company GeneDx presented a Saphyr validation study for the detection of the disease-causing variants in FSHD and repeat expansion disorders such as Mytonic Dystrophy 1 and 2.
- All previously identified cytogenetic abnormalities detected by karyotyping, FISH or microarray analysis were detected by Saphyr.
- One of the causes of ALS is an expansion of a repeat in a gene called C9orf72.
- The validation studies for FSHD, repeat expansion disorders and hematological malignancies are setting the stage for Saphyr to become a routine tool in research and clinical settings.
For each pre-funded warrant Bionano sells, the number of shares of common stock Bionano is offering will be decreased on a one-for-one basis.
Key Points:
- For each pre-funded warrant Bionano sells, the number of shares of common stock Bionano is offering will be decreased on a one-for-one basis.
- The offering is expected to close on or aboutOctober 23, 2019, subject to customary closing conditions.
- The gross proceeds to Bionano from this offering are expected to be approximately$18 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bionano, and excluding any proceeds that may be received upon exercise of the common warrants.
- Such forward-looking statements include, without limitation, statements about Bionanos expectations regarding the completion, timing and size of the public offering and the anticipated use of net proceeds therefrom.
Retrieved on:
Wednesday, October 16, 2019
PerkinElmer Genomics and the University of Iowa have developed assays based on the Bionano optical mapping technology to expand their comprehensive suite of genetic tests assessing disease-associated chromosomal abnormalities.
Key Points:
- PerkinElmer Genomics and the University of Iowa have developed assays based on the Bionano optical mapping technology to expand their comprehensive suite of genetic tests assessing disease-associated chromosomal abnormalities.
- FSHD is one of the most prevalent forms of muscular dystrophy and affects approximately 1 in 10,000 individuals.
- It is caused by changes in the number of repeats in a section of chromosome 4.
- The lack of timely and affordable genetic testing has been a major hurdle for the FSHD community.
Retrieved on:
Wednesday, October 16, 2019
Branches of biology,
Biology,
Life sciences,
Molecular biology,
Biotechnology,
DNA,
DNA sequencing,
Genetic mapping,
In science,
Optical mapping,
Genomics,
Gene mapping ASHG 2019 represents a milestone for Bionano, with a record number of presentations demonstrating novel discoveries through our genome mapping technology, said Erik Holmlin, Ph.D., CEO of Bionano.
Key Points:
- ASHG 2019 represents a milestone for Bionano, with a record number of presentations demonstrating novel discoveries through our genome mapping technology, said Erik Holmlin, Ph.D., CEO of Bionano.
- Optical mapping through Saphyr enables the direct observation of large genomic variations through imaging of fluorescently labeled, megabase-size native DNA molecules.
- Next-generation sequencing (NGS), in contrast, relies on short-reads that piece together sequence fragments in an attempt to rebuild the actual structure of the genome.
- Genome mapping resolves these structural variations for more insight into the genetic variations that cause disease.
Retrieved on:
Monday, September 9, 2019
Bionano is a life sciences instrumentation company in the genome analysis space.
Key Points:
- Bionano is a life sciences instrumentation company in the genome analysis space.
- Bionano develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to drive the adoption of digital cytogenetics, which is designed to be more systematic, streamlined and industrialized form of traditional cytogenetics.
- The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools.
A preliminary read-out by Professor Brynn Levy, Director of Cytogenetics at Columbia University, regarding 11 patient samples analyzed and unblinded from a multi-center clinical validation study.
Key Points:
- A preliminary read-out by Professor Brynn Levy, Director of Cytogenetics at Columbia University, regarding 11 patient samples analyzed and unblinded from a multi-center clinical validation study.
- This detailed characterization of variants potentially helps to enable a precise treatment tailored to the specific patients tumor.
- Based on the preliminary results, Dr. Levy concluded that Saphyr has the potential to be a powerful new tool in cytogenomics for assessing chromosome structure and copy number.
- The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools.
SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its financial results for the second quarter and six-months ended June 30, 2019 and provided a business update.
Key Points:
- SAN DIEGO, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ: BNGO), a life sciences instrumentation company that develops and markets Saphyr, a platform for ultra-sensitive and ultra-specific structural variation detection in genome analysis, today reported its financial results for the second quarter and six-months ended June 30, 2019 and provided a business update.
- Presented initial results from key clinical studies designed to evaluate the performance of Saphyr against traditional cytogenetics methods at the European Human Genetics Conference.
- We are pleased to make progress each quarter on our goal of establishing Saphyr as a best-in-class structural variation detection and discovery system, said Erik Holmlin, Ph.D., CEO of Bionano.
- The Company will host a conference call and live webcast to discuss its second quarter 2019 financial results and provide an update on business activities.
To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
Key Points:
- To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.
- An archived version of the webcast will be available for replay in the Investors section of the Bionano website.
- Bionano is a life sciences instrumentation company in the genome analysis space.
- The Saphyr system comprises an instrument, chip consumables, reagents and a suite of data analysis tools.
